Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411
Recruiting
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation
Register for Updates
Pharmacological and Behavioral Treatment After Bariatric Surgery
NCT05157698
Recruiting
This study will compare the effectiveness of behavioral and pharmacologic treatment, alone and combined, for improvements in weight loss, cardiovascular risk factors, and psychosocial functioning following metabolic and bariatric surgery.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/17/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Obesity
Register for Updates
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662
Recruiting
This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Site Number - 1621, New Haven, Connecticut
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
NCT06715124
Recruiting
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced Solid Tumors
Register for Updates
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419
Recruiting
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: Research Site, New Haven, Connecticut
Conditions: Asthma
Register for Updates
StrokeNet Thrombectomy Endovascular Platform
NCT06289985
Recruiting
STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Ischemic Stroke
Register for Updates
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251
Recruiting
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Relapsed and/or Refractory Multiple Myeloma
Register for Updates
Intradermal Influenza Vaccination
NCT06067555
Recruiting
The goal of this study is to characterize the immune response, both innate and adaptive, as well as locally and systemic, to intradermal (ID) vaccination in healthy individuals. The intervention involves intradermal administration of an FDA-approved intramuscular seasonal influenza vaccine, using an FDA-approved device MicronJet. Investigators will measure antibody titers, cell subtypes, and multi-omic profiles, by collecting skin and peripheral blood at baseline and at several time points after... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
06/16/2025
Locations: Church Street Research Unit, New Haven, Connecticut
Conditions: Vaccine Reaction
Register for Updates
Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant
NCT05203965
Recruiting
The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
06/16/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Familial Alcoholism Vulnerability
Register for Updates
Ertugliflozin in Chronic Heart Failure
NCT04438213
Recruiting
The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy. There are two general purposes for this study. The proposed study is both larger and more rigorous than essentially all PK/PD studies that form the basis of current practice with loop diuretics as well as all studies looking at add-on thiazid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Heart Failure
Register for Updates
Evolutionary Therapy for Rhabdomyosarcoma
NCT04388839
Recruiting
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
06/16/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Rhabdomyosarcoma
Register for Updates
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT04569747
Recruiting
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/15/2025
Locations: Stamford Hospital, Stamford, Connecticut
Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Register for Updates